Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's Disease Trial Design

Collaboration looks to explore the use of Darmiyan's FDA De Novo authorized BrainSee imaging platform, authorized for predicting risk of progression to Alzheimer's disease in patients with amnesti...